---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-26-000068"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2026-06-29T15:14:38+00:00"
generated_at: "2026-06-29T15:16:14.472262+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions secures $52.7M contract modification from ASPR for ACAM2000 supply

## Summary
- $52.7M modification exercises Option Year 7 under existing 10-year ASPR contract.
- Deliveries of ACAM2000 vaccine, ancillaries, and diluent begin June 2026; diluent balance by December 2026.
- Contract supports U.S. government smallpox and mpox preparedness and response needs.
- Modification follows recent ACAM2000 approvals for mpox in Saudi Arabia and Singapore.

## SEC filing metadata
- accession: 0001367644-26-000068
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2026-06-29T15:14:38+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000068/0001367644-26-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000068/ebs-20260626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-26-000068
- JSON: https://secwatch.observer/filing/0001367644-26-000068.json
- Plain text: https://secwatch.observer/filing/0001367644-26-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.